中国经济网北京12月29日讯奥浦迈(688293.SH)今日收报49.23元，跌幅5.91%。该股目前处于破发状 态。 2023年5月6日，奥浦迈公告分红方案，每10股派息(税前)6元并转增4股，除权除息日为2023年5月12 日。 奥浦迈2024年年度报告显示，肖志华及HE YUNFEN(贺芸芬)为该公司实际控制人，系夫妇关系。肖志 华，中国国籍；HE YUNFEN(贺芸芬)，美国国籍。 奥浦迈于2022年9月2日在上交所科创板上市，公开发行新股2049.51万股，发行价格为80.20元/股，保荐 机构(主承销商)为海通证券股份有限公司(现更名为国泰海通证券股份有限公司)，保荐代表人为靳宇 辰、王冰。 奥浦迈首次公开发行股票募集资金总额为164,370.56万元，扣除发行费用后，募集资金净额为151,094.48 万元。奥浦迈实际募资净额比原拟募资多100,827.94万元。奥浦迈于2022年8月30日披露的招股书显示， 该公司原拟募资50,266.54万元，分别用于奥浦迈CDMO生物药商业化生产平台、奥浦迈细胞培养研发中 心项目、补充流动资金。 奥浦迈首次公开发行股票的发行费用总额为13,276.08万元 ...

Core Viewpoint - The article discusses the acquisition of CPL Biotech by Aopumai, highlighting the fluctuating valuation of CPL Biotech and the innovative payment structure of the acquisition, which includes differentiated pricing and performance commitments from all shareholders involved in the deal [3][14]. Group 1: Acquisition Details - CPL Biotech's valuation has seen significant changes, from 220 million to 3.22 billion, and then down to 1.45 billion after an unsuccessful IPO [3]. - Aopumai plans to acquire 100% of CPL Biotech through a combination of stock issuance and cash payments, with a unique pricing structure that categorizes shareholders into four tiers with varying valuations [3][5]. - The price differences among shareholders can reach up to 1 billion, with the highest tier receiving a valuation of 2.18 billion [4][5]. Group 2: Shareholder Commitments - All 31 shareholders, including financial investors and the management team, have signed performance commitment agreements, promising specific net profit targets for 2025 to 2027 [14]. - The performance commitments require shareholders to compensate Aopumai with 10%-50% of their transaction value in case of unmet profit targets, depending on their valuation tier [14]. Group 3: Financial Performance and Market Position - CPL Biotech has shown steady revenue growth, with revenues of 318 million, 331 million, and 187 million for 2023, 2024, and the first half of 2025, respectively, but has faced declining net profits [15]. - The company has secured a significant order backlog of 252 million, reflecting a year-on-year increase of 37.68%, and has focused on high-demand areas such as large molecule innovative drugs [16]. Group 4: Aopumai's Strategic Intent - Aopumai, which has shown strong financial performance with a revenue increase of 25.79% and a net profit increase of 81.48% in 2025, aims to integrate CPL Biotech into its broader strategy of combining clinical research and manufacturing [19][20]. - The acquisition reflects Aopumai's ambition to enhance its profitability and expand its capabilities in the biopharmaceutical industry, leveraging CPL Biotech's expertise and market position [21].

上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）于2024 年10月30日召开第二届董事会第六次会议、第二届监事会第五次会议，审议通过 了《关于公司参与设立产业基金的议案》，同意公司及/或其全资子公司上海奥 浦迈生物工程有限公司（以下简称"奥浦迈生物工程"）以自有资金出资参与设 立产业基金，该产业基金现工商登记名称为上海奥创先导创业投资基金合伙企业 （有限合伙）（以下简称"奥创先导"、"合伙企业"或"产业基金"），预计 募集资金总规模为人民币10亿元，公司及/或奥浦迈生物工程拟作为有限合伙人 以自有资金认缴出资不超过基金总规模的30%且不超过人民币30,000万元。奥创 先导主要专注于对中国境内生物制造、制药设备和耗材、生物医药等领域的早中 期项目和并购项目进行直接或间接的股权或准股权投资或从事与投资相关的活 动。 证券代码：688293 证券简称：奥浦迈 公告编号：2025-117 上海奥浦迈生物科技股份有限公司 关于公司参与设立产业基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、产业基 ...

中国经济网北京12月18日讯 奥浦迈(688293.SH)今日收报51.33元，跌幅2.64%，总市值58.42亿元。 该股目前处于破发状态。 奥浦迈2024年年度报告显示，肖志华及HE YUNFEN（贺芸芬）为该公司实际控制人，系夫妇关 系。肖志华，中国国籍；HE YUNFEN（贺芸芬），美国国籍。 奥浦迈于2022年9月2日在上交所科创板上市，公开发行新股2049.51万股，发行价格为80.20元/股， 保荐机构（主承销商）为海通证券股份有限公司（现更名为国泰海通证券股份有限公司），保荐代表人 为靳宇辰、王冰。 (责任编辑：田云绯) 2023年5月6日，奥浦迈公告分红方案，每10股派息(税前)6元并转增4股，除权除息日为2023年5月 12日。 奥浦迈首次公开发行股票募集资金总额为164,370.56万元，扣除发行费用后，募集资金净额为 151,094.48万元。奥浦迈实际募资净额比原拟募资多100,827.94万元。奥浦迈于2022年8月30日披露的招 股书显示，该公司原拟募资50,266.54万元，分别用于奥浦迈CDMO生物药商业化生产平台、奥浦迈细胞 培养研发中心项目、补充流动资金。 奥浦迈首次公开 ...

Group 1: Market Trends - The number of newly added private placement projects increased to 26 in the last two weeks, a 62.5% increase from the previous period[5] - The approval rate for projects remains at 100%, with 27 projects approved by the review committee, up 171.4% from the previous period[5] - There are currently 631 projects in the normal review stage, with 92 projects having received approval, an increase of 33.33%[5] Group 2: Fundraising Dynamics - Total fundraising amount in the last two weeks was 1.567 billion yuan, a decrease of 84.48% from the previous period[29] - The average benchmark discount rate for fundraising projects dropped to 9.81%, a decrease of 10.03%[29] - The average premium rate for bidding projects increased to 10.62%, up 8.77% from the previous period[39] Group 3: Project Analysis - Aopu Mai plans to acquire a preclinical CRO service company, with an estimated valuation of 1.452 billion yuan, reflecting a 56.62% increase in value[22] - Qide New Materials aims to raise up to 275 million yuan for expanding production capacity, with a PE ratio of 211.91X, placing it in the top 30% of industry valuations[23] - The average absolute return for newly unlocked bidding projects was 36.29%, a decrease of 41.07% from the previous period[29]

Group 1 - The core viewpoint of the article highlights that the company, Aopumai, is focusing on expanding its overseas business, particularly in Europe and certain EU countries [2] - The company's overseas business proportion has been gradually increasing over recent years [2] - Aopumai has successfully passed the EU Qualified Person (QP) audit as of September 2025, which will facilitate its further expansion into the European and international markets [2]

Group 1: Market Dynamics - A total of 26 new private placement projects were added in the last two weeks, a 62.5% increase from the previous period[5] - The approval rate for projects remains at 100%, with 27 projects approved by the review committee, an increase of 171.4%[5] - There are currently 631 projects in the normal review stage, with 92 projects having received approval, an increase of 33.3%[5] Group 2: Fundraising Trends - The total fundraising amount in the last two weeks was 1.567 billion yuan, a decrease of 84.48% compared to the previous period[29] - The average benchmark discount rate for fundraising projects has dropped to 9.81%, a decrease of 10.03%[29] - The average participation rate in competitive bidding projects increased to 55.75%, up by 1.05 percentage points[29] Group 3: Performance Analysis - The average absolute return for newly unlocked competitive bidding projects was 36.29%, down by 41.07 percentage points[29] - The average market price discount rate for competitive projects was 18.38%, an increase of 1.76 percentage points[29] - The average absolute return for pricing projects was 107.39%, down by 20.09 percentage points[29] Group 4: Risk Factors - Risks include slower-than-expected review progress, fluctuations in secondary market stock prices, and changes in the market environment for private placements[5]

Core Viewpoint - The company is focusing on expanding its overseas business, particularly in European countries, including some EU nations, and has achieved a significant milestone by passing the EU Quality Authorization audit, which will facilitate further market expansion [1] Group 1 - The company's overseas business is primarily concentrated in Europe and certain EU countries [1] - The proportion of the company's overseas business has been gradually increasing in recent years [1] - The company has passed the EU Quality Authorization audit, which is expected to accelerate its expansion into the European and international markets by September 2025 [1]

Core Insights - The report emphasizes the continuous improvement of the global competitiveness of Chinese innovative pharmaceutical companies, focusing on innovation from both "therapeutic areas" and "technology platforms" [5][6] - The growth of commercial health insurance premiums is expected to provide new payment sources for medical expenses, as the scale of commercial health insurance is projected to reach 977.4 billion yuan by 2024 [29][30] - The report identifies potential therapeutic areas such as metabolic diseases (e.g., weight loss), chronic diseases (e.g., hypertension, hyperlipidemia), and central nervous system diseases (e.g., Alzheimer's, Parkinson's) as key focus areas for innovation [5][38] - Emerging technology platforms like small nucleic acid drugs, radioactive drugs (RDC), and CAR-T therapies are highlighted as significant areas for investment [5][38] Market Review - As of November 15, 2025, the pharmaceutical sector has outperformed the market, with the pharmaceutical index rising by 22.09% compared to a 17.62% increase in the CSI 300 index, resulting in a 4.47 percentage point outperformance [11] - The chemical preparation sector showed the best performance, increasing by 40.52%, followed by medical services (+36.98%) and chemical raw materials (+25.34%) [20] - The overall PE valuation of the pharmaceutical sector is at 30.89 times, which is relatively low compared to historical averages, indicating potential for future growth [22][23] Innovative Drugs - The report notes that the growth of health expenditures in China, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating a robust market for innovative drugs [26][27] - The analysis of multinational corporations (MNCs) reveals that innovation is a core competitive advantage, with companies like Eli Lilly and Novartis showing significant growth driven by innovative products in advanced technology fields such as GLP-1 and ADC [31][32] - The report highlights the strong sales performance of GLP-1 drugs, with Eli Lilly's Mounjaro generating $6.515 billion in revenue in Q3 2025, reflecting a 109% year-on-year increase [44] CXO and Upstream - The report indicates a slight increase in pharmaceutical financing, with a recovery in business development transactions and H-share IPOs, which is expected to stimulate innovation [5] - The demand for external CXO services is growing, particularly in emerging fields such as peptides and small nucleic acids, while internal CXO orders are also showing signs of recovery [5][39] Medical Devices - The domestic medical device market is currently under pressure due to policy impacts, but improvements are anticipated as companies continue to innovate and expand internationally [5] - The report suggests that the industry fundamentals are expected to improve, with a focus on companies like Mindray Medical and Microelectrophysiology [5][39]

Group 1 - Unicom Guowei has established a Central Research Institute focusing on the development of edge AI chips for applications in autonomous driving, embodied robots, and low-altitude flying vehicles [2] - The research will also include new types of storage devices based on two-dimensional materials and high-performance special sensor chips [2] - Aerospace Electronics plans to increase its investment in Aerospace Long March Rocket Technology Co., Ltd. by 728 million yuan, maintaining the existing shareholding structure [3] Group 2 - Aerospace Rainbow successfully completed the first flight test of its self-developed Rainbow-7 high-altitude, high-speed, long-endurance drone, achieving all preset parameters [4] - The project is still in the research and testing phase, with further rigorous testing and validation required before mass production [4] Group 3 - Changchun High-tech's subsidiary signed an exclusive licensing agreement for the GenSci098 injection project, potentially earning up to 1.365 billion USD in milestone payments [5] - The agreement includes an initial payment of 120 million USD and additional milestone payments related to development and commercialization [5] Group 4 - TCL Technology plans to acquire a 10.7656% stake in Shenzhen Huaxing Semiconductor for 6.045 billion yuan, increasing its ownership from 84.2105% to 94.9761% [26] - This acquisition aims to enhance TCL's competitiveness and profitability in the semiconductor display industry [26] Group 5 - Zhongmin Resources announced the successful ignition of its Tsumeb smelting plant's multi-metal comprehensive recycling project, with an annual processing capacity of 80,000 tons [11] - The project will produce various products, including germanium ingots and zinc ingots, with a design capacity of 33 tons/year for germanium [11] Group 6 - Xinhua Insurance reported a 16% year-on-year increase in original insurance premium income, totaling 188.85 billion yuan from January to November 2025 [43] - This growth reflects the company's strong performance in the insurance market [43]